Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE versus PAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE versus PAMINE.
ATROPINE vs PAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine and other cholinergic agonists. Inhibits vagal activity, increases heart rate, reduces secretions, and relaxes smooth muscle.
Antimuscarinic; competitively blocks acetylcholine at muscarinic receptors, reducing smooth muscle spasm and secretions.
0.5-1 mg IV/IM/SC every 3-5 minutes as needed, up to a total of 3 mg (adults). For preoperative use, 0.4-0.6 mg IM/IV 30-60 minutes before anesthesia.
2.5 mg orally or subcutaneously 30-60 minutes before meals and at bedtime; maximum 10 mg/day.
None Documented
None Documented
2-4 hours (terminal); prolonged in elderly and neonates; clinically requires dosing every 4-6 hours
Clinical Note
moderateBenzatropine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Benzatropine."
Clinical Note
moderateDopamine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dopamine."
Clinical Note
moderateDopamine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dopamine."
Clinical Note
moderateDopamine + Cyclosporine
1.5-2 hours, necessitating dosing every 4-6 hours for sustained therapeutic effect.
Renal (30-50% unchanged; remainder as inactive metabolites via hydrolysis and glucuronidation); 50-70% of a dose renally excreted as metabolites; <5% fecal
Primarily renal (70-80% unchanged), with 20-30% fecal via biliary elimination.
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent
"The metabolism of Cyclosporine can be decreased when combined with Dopamine."